Evidence map›Paper›PMID 25336457›Full record

ArticlemBio2014

Origin in Acinetobacter guillouiae and dissemination of the aminoglycoside-modifying enzyme Aph(3')-VI.

Eun-Jeong Yoon, Sylvie Goussard, Marie Touchon, Lenka Krizova, Gustavo Cerqueira, Cheryl Murphy, Thierry Lambert, Catherine Grillot-Courvalin, Alexandr Nemec, Patrice Courvalin

Open access · goldAbstract read
In one paragraph

Article in mBio, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Article
  3. History of the taxonomy ofInternational journal of systematic and evolutionary microbiology · 2025
    Article
  4. Article
  5. Article
  6. Antibiotics (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Complete Genome Sequencing ofGenome announcements · 2018
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 3 countries.

Eun-Jeong YoonInstitut Pasteur, Unité des Agents Antibactériens, Paris, France.
Sylvie GoussardInstitut Pasteur, Unité des Agents Antibactériens, Paris, France.
Marie Touchon
Lenka KrizovaLaboratory of Bacterial Genetics, National Institute of Public Health, Prague, Czech Republic.
Gustavo CerqueiraBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Cheryl MurphyBroad Institute of Harvard and MIT, Cambridge, Massachusetts, USA.
Thierry LambertEA4043, Faculté de Pharmacie, Université Paris Sud, Châtenay-Malabry, France.
Catherine Grillot-CourvalinInstitut Pasteur, Unité des Agents Antibactériens, Paris, France.
Alexandr NemecLaboratory of Bacterial Genetics, National Institute of Public Health, Prague, Czech Republic.
Patrice CourvalinInstitut Pasteur, Unité des Agents Antibactériens, Paris, France patrice.courvalin@pasteur.fr.
Institut Pasteur · FRBroad Institute · USNational Institute of Public Health · CZCentre National de la Recherche Scientifique · FRUniversité Paris-Sud · FR

Funding

European Research Council 281605NIAID NIH HHS HHSN272200900018C
6 · The paper itself

Abstract

The amikacin resistance gene aphA6 was first detected in the nosocomial pathogen Acinetobacter baumannii and subsequently in other genera. Analysis of 133 whole-genome sequences covering the taxonomic diversity of Acinetobacter spp. detected aphA6 in the chromosome of 2 isolates of A. guillouiae, which is an environmental species, 1 of 8 A. parvus isolates, and 5 of 34 A. baumannii isolates. The gene was also present in 29 out of 36 A. guillouiae isolates screened by PCR, indicating that it is ancestral to this species. The Pnative promoter for aphA6 in A. guillouiae and A. parvus was replaced in A. baumannii by PaphA6, which was generated by use of the insertion sequence ISAba125, which brought a -35 sequence. Study of promoter strength in Escherichia coli and A. baumannii indicated that PaphA6 was four times more potent than Pnative. There was a good correlation between aminoglycoside MICs and aphA6 transcription in A. guillouiae isolates that remained susceptible to amikacin. The marked topology differences of the phylogenetic trees of aphA6 and of the hosts strongly support its recent direct transfer within Acinetobacter spp. and also to evolutionarily remote bacterial genera. Concomitant expression of aphA6 must have occurred because, contrary to the donors, it can confer resistance to the new hosts. Mobilization and expression of aphA6 via composite transposons and the upstream IS-generating hybrid PaphA6, followed by conjugation, seems the most plausible mechanism. This is in agreement with the observation that, in the recipients, aphA6 is carried by conjugative plasmids and flanked by IS that are common in Acinetobacter spp. Our data indicate that resistance genes can also be found in susceptible environmental bacteria. Importance: We speculated that the aphA6 gene for an enzyme that confers resistance to amikacin, the most active aminoglycoside for the treatment of nosocomial infections due to Acinetobacter spp., originated in this genus before disseminating to phylogenetically distant genera pathogenic for humans. Using a combination of whole-genome sequencing of a collection of Acinetobacter spp. covering the breadth of the known taxonomic diversity of the genus, gene cloning, detailed promoter analysis, study of heterologous gene expression, and comparative analysis of the phylogenetic trees of aphA6 and of the bacterial hosts, we found that aphA6 originated in Acinetobacter guillouiae, an amikacin-susceptible environmental species. The gene conferred, upon mobilization, high-level resistance to the new hosts. This work stresses that nonpathogenic bacteria can act as reservoirs of resistance determinants, and it provides an example of the use of a genomic library to study the origin and dissemination of an antibiotic resistance gene to human pathogens.

Indexed as

AcinetobacterAmino Acid SequenceAminoglycosidesAnti-Bacterial AgentsBase SequenceCluster AnalysisConjugation, GeneticDrug Resistance, BacterialEnvironmental MicrobiologyEscherichia coliEvolution, MolecularGene Transfer, HorizontalInterspersed Repetitive SequencesKanamycin KinaseMicrobial Sensitivity TestsMolecular Sequence DataAminoglycosidesAnti-Bacterial AgentsKanamycin Kinase

Identifiers

PMID25336457
PMCPMC4212838
OpenAlexW2168986190

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.